Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

William J. Sandborn, Julián Panés, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baía, Raja Atreya, Remo Panaccione, Grażyna Rydzewska, Humberto Aguilar, Séverine Vermeire